ImmunoResponse Predictor: a GUI for accurate response prediction to immunotherapy
PeerJ · 06.08.2026 · 14 · e21553
DOI: 10.7717/peerj.21553 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, online erschienen am 06.08.2026. Verfasst von Rajat Butola und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Statistical Science, Academia Sinica, Taipei, Taiwan. Hauptthemen laut MEDLINE: Immunotherapy, Immune Checkpoint Inhibitors, Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute of Statistical Science, Academia Sinica, Taiwan, Precision Medicine group grant, National Science & Technology Council, Taiwan, Republic of China, NSTC.
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICIs) have improved outcomes for subsets of patients with metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC), yet objective response rates remain low (∼15–25%), underscoring the need for tools that support patient stratification. We previously developed LogitDA, a logistic regression–based predictor incorporating feature selection and domain adaptation, which outperformed established immune-related signatures in predicting response to the PD-L1 inhibitor atezolizumab. Here, we present the ImmunoResponse Predictor, a web-based clinical decision-support framework that enables responsible application of LogitDA in real-world settings. The system integrates standardized transcriptomic preprocessing, interpretable individual-level predictions (including single-sample use), clinically motivated LogitDA score cutoffs that prioritize minimization of false negatives, and a cohort-level percentage of applicability with empirically derived thresholds designed to assess whether predictions can be reliably extrapolated to newly uploaded datasets. Importantly, applicability functions as a diagnostic safeguard against distributional shift rather than as a response predictor. We evaluated the framework across four independent cohorts, PCD4989g(mUC), PCD4989g(mRCC), the Moreno cohort, and the UNC-108 cohort. LogitDA achieved prediction accuracies of 0.69, 0.83, 0.86, and 0.53, with corresponding applicability estimates of 74%, 76%, 71%, and 48%, respectively, correctly identifying the UNC-108 cohort as one in which predictions warrant increased caution. Overall, the ImmunoResponse Predictor extends LogitDA into a practical, interpretable, and safeguarded tool for immunotherapy response prediction, supporting cautious clinical and translational use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Statistical Science, Academia Sinica, Taipei, Taiwan.
- Bioinformatics Program, Taiwan International Graduate Program, Academia Sinica, Taipei, Taiwan.
- Genome and Systems Biology Degree Program, Academia Sinica, National Taiwan University, Taipei, Taiwan.
- Data Science Degree Program, Academia Sinica and National Taiwan University, Taipei, Taiwan.
Förderung
- Institute of Statistical Science, Academia Sinica, Taiwan, Precision Medicine group grant
- National Science & Technology Council, Taiwan, Republic of China, NSTC
Zitieren
APA
Butola, R., Yuan, S., & Shieh, G. S. (2026). ImmunoResponse Predictor: a GUI for accurate response prediction to immunotherapy. PeerJ, 14, e21553. https://doi.org/10.7717/peerj.21553
Vancouver
Butola R, Yuan S, Shieh GS. ImmunoResponse Predictor: a GUI for accurate response prediction to immunotherapy. PeerJ. 2026;14:e21553. doi:10.7717/peerj.21553
BibTeX
@article{Butola2026,
author = {Butola, Rajat and Yuan, Shinsheng and Shieh, Grace S},
title = {ImmunoResponse Predictor: a GUI for accurate response prediction to immunotherapy},
journal = {PeerJ},
year = {2026},
volume = {14},
pages = {e21553},
doi = {10.7717/peerj.21553}
}
EUVIMED